Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.

US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.

Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

In honor of its former secretary-general DG Shah, the Indian Pharmaceutical Alliance has created a public policy award at the Indian Institute of Management in Ahmedabad.

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.

Biocon-Mylan’s sBLA for pegfilgrastim made at a new Indian site gets an FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.

Medicines For Europe has called on EU leaders to take action on the issue of medicine shortages, urging the new European Commission to prioritize shortage prevention in its first 100 days.

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.

Krka has revealed its new growth strategy for 2020-2024, including growing through joint ventures, partnerships and acquisitions and focusing on European, central Asian and Chinese markets. At the same time, the Slovenian firm has reported that its sales jumped by 12% in the first nine months of 2019.

EU member states are being urged by the European Commission to cooperate more closely on pricing and reimbursement, managed access deals and policies to promote generics and biosimilars.

Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.

Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.

Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.

Incentives for innovation around known molecules and new guidelines for value added medicines are needed, Medicines for Europe has insisted at the organization’s value added medicines conference in Brussels yesterday. The European off-patent industry association has called for a “pragmatic value framework” to recognize value added medicines, as well as welcoming the advent of digital health solutions.